Related Experiment Video
Updated: Sep 6, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Pharmacogenomic and Medicinal Chemistry Perspectives on Off-label Drug Use
Mariana Meira Scudeler1, Isadora Renck Scherer1, Gabriel Vaisam Castro1
1Department of Cell Biology, Embryology, and Genetics, Center for Biological Sciences, Federal University of Santa Catarina, Florianópolis, Brazil.
Introduction:
Off-label drug use (OLDU) is frequent in populations insufficiently represented in clinical trials, including pediatrics, rare diseases, and psychiatry. Although it broadens therapeutic options, uncertainty regarding safety and response remains a central concern. Physical chemistry properties influence drug distribution, target promiscuity, and exposure profiles in offlabel contexts. Because the biological processes that translate these intrinsic molecular properties into pharmacokinetic and pharmacodynamic phenotypes are modulated by genetic variability, pharmacogenomics may provide a complementary strategy for anticipating interindividual differences in safety and efficacy.
Materials And Methods:
This narrative review integrates pharmacogenomics (PGx) evidence from curated clinical resources (ClinPGx, CPIC, DPWG, and regulatory sources) with principles of medicinal chemistry, prioritizing mechanistic evidence linking genetic variability to drug response variability in commonly prescribed off-label therapies across selected therapeutic areas.
Results:
Across the therapeutic areas examined, several drugs with frequent off-label use were identified as having available pharmacogenetic information. A subset of these agents was further discussed, considering mechanistic considerations derived from medicinal chemistry principles.
Discussion:
Intrinsic molecular characteristics help explain biodistribution patterns and off-target effects observed during off-label prescribing. Gene-drug interactions involving metabolizing enzymes and transporters consistently influence drug response. Evidence specifically designed for OLDU remains limited.
Conclusion:
The convergence of medicinal chemistry and pharmacogenomics may offer a promising framework to enhance safety and precision in off-label prescribing. Although direct evidence in these settings remains limited, the established influence of genetic variation on drug pharmacokinetics and pharmacodynamics provides a biologically plausible rationale for exploring PGx-guided approaches in OLDU.
Related Concept Videos
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
